Lonza announced on Dec. 8, 2021 that it has entered into a research license agreement with Zhejiang Doer Biologics, a clinical-stage biopharmaceutical company. Doer plans to use the technology to develop, express, and manufacture multi-specific Volatile Halogenated Hydrocarbons (VHH)-based biotherapeutic proteins with the intent of addressing unmet immuno-oncology needs. Source: Biopharm International 9/12/2021